MaaT Pharma Faces Regulatory Hurdle as Cash Runway Extends to November 2026
Event summary
- MaaT Pharma reported EUR 18.1 million in cash as of March 31, 2026, with a cash runway extended to November 2026 following a EUR 6 million drawdown from the EIB loan.
- The company received a 'negative trend' indication from EMA’s CHMP ahead of the June 2026 vote on MaaT013 (Xervyteg®), planning a re-examination if the vote is unfavorable.
- Q1 2026 revenues were EUR 0.8 million, down from EUR 1.1 million in Q1 2025 due to a change in revenue accounting post-EAP transition to Clinigen.
- The PHOEBUS Phase 2 trial for MaaT033 in allo-HSCT is ongoing, with topline results expected in Q4 2028.
- The IMMUNOLIFE trial for MaaT033 in combination with Regeneron’s Cemiplimab could report topline results in H1 2026.
The big picture
MaaT Pharma is navigating a critical regulatory phase for its lead candidate, MaaT013 (Xervyteg®), while managing its cash position to support ongoing clinical trials. The company’s ability to secure regulatory approval and maintain financial stability will be key to its long-term success in the competitive microbiome-driven immunotherapy space. The strategic shift in revenue accounting post-EAP transition to Clinigen highlights the operational adjustments necessary to sustain growth.
What we're watching
- Regulatory Headwinds
- Whether MaaT Pharma can successfully navigate the re-examination process for MaaT013 (Xervyteg®) following the negative trend indication from EMA’s CHMP.
- Cash Management
- The pace at which MaaT Pharma can extend its cash runway beyond November 2026 to support upcoming regulatory and clinical milestones.
- Clinical Development
- How the topline results from the IMMUNOLIFE and PHOEBUS trials will impact the strategic direction and funding requirements for MaaT Pharma’s pipeline.
Related topics